Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Daniel Geynisman

Email
Center AffiliationsCancer Prevention and Control

Publications (48) (print view)

paginate
Abbosh P, Sundararajan S, Millis SZ, Hauben A, Reddy S, Geynisman DM, Uzzo R. Molecular and Genomic Profiling to Identify Actionable Targets in Chromophobe Renal Cell Cancer. European urology focus. 2017 Jan 23;.
Ali N, Kutikov A, Geynisman DM. Resolution of a Debilitating Paraneoplastic Parkinson-like Neurological Syndrome Following Tyrosine Inhibitor Therapy and Consolidative Nephrectomy in a Patient with Advanced Clear Cell Renal Cell Carcinoma. Urol Case Rep. 2017 Sep;14:18-20.   PMCID: PMC5479944
Cahn DB, Handorf EA, Ghiraldi EM, Ristau BT, Geynisman DM, Churilla TM, Horwitz EM, Sobczak ML, Chen DY, Viterbo R, Greenberg RE, Kutikov A, Uzzo RG, Smaldone MC. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. Cancer. 2017 Jul 25;123(22):4337-45.
Cahn DB, Handorf E, Ristau BT, Geynisman DM, Simhan J, Kutikov A, Greenberg RE, Viterbo R, Chen DY, Uzzo RG, Smaldone MC. Contemporary practice patterns and survival outcomes for locally advanced urethral malignancies: A National Cancer Database Analysis. Urol Oncol. 2017 Aug 10;35(12):670 e15-670 e21.
Geynisman DM. Hope and Uncertainty in the Age of Miracles. J Palliat Med. 2017 Oct;20(10):1166-9.
Geynisman DM, de Velasco G, Sewell KL, Jacobs I. Biosimilar biologic drugs: a new frontier in medical care. Postgraduate medicine. 2017 May;129(4):460-70.
Geynisman DM, Plimack ER. Bending the Curve of Advanced Urothelial Carcinoma. J Oncol Pract. 2017 May;13(5):319-20.
Ghatalia P, Nagarathinam R, Cooper H, Geynisman DM, El-Deiry WS. Mismatch repair deficient metastatic colon cancer and urothelial cancer: a case report of sequential immune checkpoint therapy. Cancer Biol Ther. 2017 Sep 02;18(9):651-4.   PMCID: PMC5663404
Ghatalia P, Zibelman M, Geynisman DM, Plimack ER. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma. Current treatment options in oncology. 2017 Jan;18(1):7.
Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras A, Park JC, Chapman C, Masterson TA, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu Z, Albany C, Moore ML, Loman RA, Reed A, Turner SA, de Abreu FB, Gallagher TL, Tsongalis GJ, Plimack ER, Greenberg RE, Geynisman DM. A Phase Ii Trial of Dovitinib in Bcg-Unresponsive Urothelial Carcinoma with Fgfr3 Mutations or over-Expression: Hoosier Cancer Research Network Trial Hcrn 12-157. Clin Cancer Res. 2017 Jun 15;23(12):3003-11.   PMCID: PMC5462889
Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras A, Park JC, Chapman C, Masterson TA, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu ZY, Albany C, Moore ML, Loman RL, Reed A, Turner SA, De Abreu FB, Gallagher T, Tsongalis GJ, Plimack ER, Greenberg RE, Geynisman DM. A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. Clinical Cancer Research. 2017 Jun;23(12):3003-11.
Judd J, Zibelman M, Handorf E, O'Neill J, Ramamurthy C, Bentota S, Doyle J, Uzzo RG, Bauman J, Borghaei H, Plimack ER, Mehra R, Geynisman DM. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. The oncologist. 2017 Jun 26;22(10):1232-7.   PMCID: PMC5634771
Jung K, Ghatalia P, Litwin S, Horwitz EM, Uzzo RG, Greenberg RE, Viterbo R, Geynisman DM, Kutikov A, Plimack ER, Smaldone MC, Wong YN, Bilusic M. Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. Clin Genitourin Cancer. 2017 Sep 30;15(3):e337-e343.
Meeker CR, Wong YN, Egleston BL, Hall MJ, Plimack ER, Martin LP, Von Mehren M, Lewis BR, Geynisman DM. Distress and financial distress in adults with cancer: An age-based analysis. JNCCN Journal of the National Comprehensive Cancer Network. 2017 Oct;15(10):1224-33.
Necchi A, Pond GR, Raggi D, Ottenhof SR, Djajadiningrat RS, Horenblas S, Khoo V, Hakenberg OW, Draeger D, Protzel C, Heidenreich A, Haidl F, Eigl BJ, Nappi L, Matsumoto K, Vaishampayan U, Woods ME, Salvioni R, Nicolai N, Catanzaro M, Giannatempo P, Geynisman DM, Preto M, Xylinas E, Milowsky MI, De Placido S, Di Lorenzo G, Sonpavde G. Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. Clin Genitourin Cancer. 2017 Oct;15(5):548-555 e3.
Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. Eur Urol. 2017 May 30;.
Ramamurthy C, Doyle J, Uzzo RG, Kutikov A, Smaldone MC, Geynisman DM. Role of collaboration between urologists and medical oncologists in the advanced prostate cancer space. Urol Oncol. 2017 Jul 15;.   PMCID: Editorial
Ristau BT, Geynisman DM. Patient-reported and Cost-effectiveness Outcomes Are Key to Determining the Optimal Therapeutic Sequence for Patients with Metastatic Renal Cell Carcinoma. Eur Urol. 2017 Feb;71(2):210-2.   PMCID: Editorial
Shaikh T, Li T, Handorf EA, Johnson ME, Wang LS, Hallman MA, Greenberg RE, Price RA, Uzzo RG, Ma C, Chen D, Geynisman DM, Pollack A, Horwitz EM. Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):722-31.   PMCID: PMC5331910
Tong C, Daskalakis N, Edwards DC, Cahn DB, Belkoff L, Geynisman DM. Malignant Infiltration of the Penis From Urothelial Carcinoma of the Bladder. Urology. 2017 Sep;107:23-5.
Beck TN, Golemis EA, Geynisman DM. Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4. Eur Urol. 2016 Mar 03;70(3):e75-6.   PMCID: PMC4975993
Beck TN, Golemis EA, Geynisman DM. Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4. European Urology. 2016 Sep;70(3):E75-E76.
Cahn DB, Ristau BT, Ghiraldi EM, Churilla TM, Geynisman DM, Horwitz EM, Uzzo RG, Smaldone MC. Bladder Preservation Therapy: A Review of the Literature and Future Directions. Urology. 2016 Oct;96:54-61.
Cahn DB, Ristau BT, Ghiraldi EM, Churilla TM, Geynisman DM, Horwitz EM, Uzzo RG, Smaldone MC. Bladder Preservation Therapy: A Review of the Literature and Future Directions. Urology. 2016 May 30;96:54-61.
Geynisman DM. When Patients Leave. J Clin Oncol. 2016 Feb 10;34(5):509-10.
Geynisman DM, Handorf E, Wong YN, Doyle J, Plimack ER, Horwitz EM, Canter DJ, Uzzo RG, Kutikov A, Smaldone MC. Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer medicine. 2016 Feb;5(2):192-9.   PMCID: 4735777
Geynisman DM, Plimack ER, Zibelman M. Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?. Eur Urol. 2016 Dec;70(6):971-3.   PMCID: Editorial
Geynisman DM, Wong YN. Drug Supply Chain Security Act and Oral Anticancer Medications: Are We Shortchanging Our Patients?. JAMA Oncol. 2016 Mar;2(3):295-6.
Geynisman DM, Wong YN. Drug Supply Chain Security Act and Oral Anticancer Medications: Are We Shortchanging Our Patients?. JAMA Oncol. 2016 Mar;2(3):295-6.
Kircher SM, Meeker CR, Nimeiri H, Geynisman DM, Zafar SY, Shankaran V, de Souza J, Wong YN. The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?. Value Health. 2016 Jan;19(1):88-98.
Meeker CR, Geynisman DM, Egleston BL, Hall MJ, Mechanic KY, Bilusic M, Plimack ER, Martin LP, von Mehren M, Lewis B, Wong YN. Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. J Oncol Pract. 2016 Jun 21;12(7):e755-64.   PMCID: PMC5015446
Nadal R, Amin A, Geynisman DM, Voss MH, Weinstock M, Doyle J, Zhang Z, Viudez A, Plimack ER, McDermott DF, Motzer R, Rini B, Hammers HJ. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)- tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Ann Oncol. 2016 Jul;27(7):1304-11.
Plimack ER, Geynisman DM. Targeted Therapy for Metastatic Urothelial Cancer: A Work in Progress. J Clin Oncol. 2016 May 09;34(18):2088-92.
Zibelman M, Ghatalia P, Geynisman DM, Plimack ER. Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. Immunotherapy. 2016 Jun;8(7):785-98.
Barth P, Dulaimi Al-Saleem E, Edwards KW, Millis SZ, Wong YN, Geynisman DM. Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature. Case Rep Oncol Med. 2015 Jan;2015:895151.   PMCID: Pmc4322830
Geynisman DM. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol. 2015 Jul 17;68(5):912-4.
Geynisman DM. E-mail anonymous: a physician's addiction. J Clin Oncol. 2015 Jan 20;33(3):285-6.
Geynisman DM, Hu JC, Liu L, Tina Shih YC. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States. Clin Genitourin Cancer. 2015 Apr;13(2):e93-100.
Geynisman DM, Ross EA, Plimack ER. Osteoclast Inhibitors in Advanced Prostate Cancer: Does the Benefit Extend Beyond Skeletal-Related Events?. Eur Urol. 2015 Jun 23;68(4):578-80.   PMCID: NA Editorial
Geynisman DM, Szmulewitz RZ, Plimack ER. Corticosteroids and prostate cancer: Friend or foe? [Comment; Editorial]. European Urology. 2015 Jan;67(5):874-5.   PMCID: NA Editorial
Knollman H, Godwin JL, Jain RI, Wong YN, Plimack ER, Geynisman DM. Muscle-invasive urothelial bladder cancer: An update on systemic therapy. Therapeutic Advances in Urology. 2015 Jan;7(6):312-30.   PMCID: 4647143
Seeger-Nukpezah T, Geynisman DM, Nikonova AS, Benzing T, Golemis EA. The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease. Nat Rev Nephrol. 2015 Sep;11(9):515-34.
Shih YC, Smieliauskas F, Geynisman DM, Kelly RJ, Smith TJ. Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011. J Clin Oncol. 2015 Jul;33(19):2190-6.   PMCID: 4477789
Tomaszewski JJ, Uzzo RG, Egleston B, Corcoran AT, Mehrazin R, Geynisman DM, Ridge JA, Veloski C, Kocher N, Smaldone MC, Kutikov A. Coupling of Prostate and Thyroid Cancer Diagnoses in the United States. Annals of Surgical Oncology. 2015 Mar;22(3):1043-9.   PMCID: 4419700
Zibelman M, Barth P, Handorf E, Smaldone MC, Kutikov A, Uzzo RG, Bilusic M, Plimack ER, Wong YN, Geynisman DM. A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite. Clin Genitourin Cancer. 2015 Apr;13(2):142-9.
Geynisman DM, Chien CR, Smieliauskas F, Shen C, Shih YC. Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review. Hum Vaccin Immunother. 2014 Jan;10(11):3415-24.   PMCID: PMC4514043
Godwin JL, Zibelman M, Plimack ER, Geynisman DM. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discov Med. 2014 Dec;18(101):341-50.
Shen C, Chien CR, Geynisman DM, Smieliauskas F, Shih YC. A review of economic impact of targeted oral anticancer medications. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):45-69.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Daniel Geynisman Sparkline Graph

Graph Interactions

Co-Authors:

Similar Investigators:


Keywords (MeSH):


Last updated on Monday, December 04, 2017